OtoKinetics Inc.
Acoustic stimulation of cochlear fluid improves hearing
This article was originally published in Start Up
Executive Summary
Currently, people with severe hearing loss are treated with conventional hearing aids, which have less than a 50% success rate due to such problems as feedback and discomfort. OtoKinetics Inc. hopes to increase that efficacy rate to at least 90% with its Krescendo implant, a titanium device about the size of a grain of rice that is inserted into the cochlea.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.